A Multicenter, Randomized, Open Label, Controlled Study Evaluating the Effectiveness and Safety of Furoscix On-Body Infusor vs Continued Medical Therapy for Worsening Heart Failure

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 May 2023 According to a scPharmaceuticals media release, data from this study were presented at the Technology and Heart Failure Therapeutics Conference 2023.
22 Mar 2023 According to a scPharmaceuticals media release, data from this study will be presented at the Technology and Heart Failure Therapeutics Conference, March 20-22, 2023.
30 Sep 2022 According to scPharmaceuticals Media Release, results from this trial were presented at the Heart Failure Society of America (HFSA) 2022 Annual Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com